Production (Stage)
ProQR Therapeutics N.V.
PRQR
$1.79
-$0.02-1.11%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.76M | 4.59M | 4.22M | 6.79M | 4.83M |
| Total Other Revenue | 233.60K | 145.00K | 151.70K | 167.90K | 228.00K |
| Total Revenue | 4.99M | 4.74M | 4.38M | 6.95M | 5.06M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 4.99M | 4.74M | 4.38M | 6.95M | 5.06M |
| SG&A Expenses | 3.40M | 4.17M | 3.61M | 3.24M | 3.75M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.37M | 15.48M | 13.96M | 10.83M | 13.82M |
| Operating Income | -11.38M | -10.75M | -9.58M | -3.87M | -8.77M |
| Income Before Tax | -10.61M | -9.92M | -8.91M | -3.11M | -8.31M |
| Income Tax Expenses | -- | 0.00 | -- | -215.30K | 3.30K |
| Earnings from Continuing Operations | -10.61M | -9.92M | -8.91M | -2.90M | -8.31M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.61M | -9.92M | -8.91M | -2.90M | -8.31M |
| EBIT | -11.38M | -10.75M | -9.58M | -3.87M | -8.77M |
| EBITDA | -10.67M | -10.51M | -8.83M | -3.11M | -8.02M |
| EPS Basic | -0.10 | -0.10 | -0.11 | -0.04 | -0.10 |
| Normalized Basic EPS | -0.06 | -0.06 | -0.07 | -0.02 | -0.06 |
| EPS Diluted | -0.11 | -0.10 | -0.11 | -0.04 | -0.10 |
| Normalized Diluted EPS | -0.06 | -0.06 | -0.07 | -0.02 | -0.06 |
| Average Basic Shares Outstanding | 105.30M | 99.43M | 81.68M | 81.67M | 81.57M |
| Average Diluted Shares Outstanding | 105.30M | 99.43M | 81.68M | 81.67M | 81.57M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |